Evonik Industries AG (EVKIF)
OTC PINK OTC PINK Primary 
Evonik: Revised Outlook Necessitates A Q3 2025 Update
Evonik Industries remains a fundamentally strong specialty chemicals company, now trading at attractive valuations despite recent earnings downgrades and market underperformance. EVKIY faces near-term headwinds, including weaker EBITDA guidance, persistent demand softness, and potential dividend risk, but maintains a BBB+ rating and manageable leverage. At current prices below €15/share, the risk/reward profile is compelling, with a conservative price target cut to €20/share and an ADR target of $11.50/share.
Look Beyond The Volatility In Evonik Industries
Evonik remains a 'Buy' for me, offering a solid 7%+ yield and BBB+ rating despite recent underperformance and macro headwinds. Short-term volatility and earnings declines are expected, but I see these as transitory, with long-term fundamentals and EU reshoring trends supporting recovery. Valuation is compelling: at current levels, EVKIY offers potential 15%+ annualized upside, with a fair value target of €22/share and significant peer appeal.
Evonik Industries AG (EVKIF) Q2 2025 Earnings Call Transcript
Evonik Industries AG (OTCPK:EVKIF) Q2 2025 Earnings Conference Call August 1, 2025 5:00 AM ET Executives Christian Kullmann – CEO & Chairman of the Executive Board Maike Schuh – CFO & Member of Executive Board Tim Lange – Head of Investor Relations Analysts Anil Shenoy - Barclays Bank PLC, Research Division Chetan Udeshi - JPMorgan Chase & Co, Research Division David Symonds - BNP Paribas Exane, Research Division Georgina Fraser - Goldman Sachs Group, Inc., Research Division Martin Roediger - Kepler Cheuvreux, Research Division Matthew John Peter Yates - BofA Securities, Research Division Thomas P. Wrigglesworth - Morgan Stanley, Research Division Operator Ladies and gentlemen, welcome to the Evonik Industries AG Q2 2025 Earnings Conference Call.
Evonik: Decent Rate Of Return, Upside Confirmed
Evonik Industries has shown significant growth, with a 25% EBITDA increase and a 42% FCF rise, making it a strong investment. The company's reorganization and focus on renewables position it well for future growth, despite current macroeconomic volatility. My price target for Evonik is €24.5/share, with a "Buy" rating due to its undervaluation and potential for long-term gains.
Evonik Industries AG (EVKIF) Q4 2024 Earnings Call Transcript
Evonik Industries AG (OTCPK:EVKIF) Q4 2024 Earnings Conference Call March 5, 2025 8:00 AM ET Company Participants Christian Kullmann - Chairman of the Executive Board Maike Schuh - Chief Financial Officer Conference Call Participants Andreas Heine - Stifel Chetan Udeshi - JPMorgan Sebastian Bray - Berenberg Martin Roediger - Kepler Cheuvreux Georgina Iwamoto - Goldman Sachs Christian Kullmann Thanks a lot, and welcome, ladies and gentlemen, to our full-year earnings call. We have four key messages that we want to bring across today.
Evonik: A Good Company, Upside Less Clear Than Before
Evonik's restructuring into growth and efficiency segments, with a focus on premiumization and defensive markets, has shown mixed results amid challenging industrial macro conditions. Despite a stable 3Q24 with improved EBITDA and cost savings, the company's forecasted growth has not fully materialized, leading to a conservative "Buy" rating. The company's high dividend yield, conservative credit rating, and potential for earnings reversal present an attractive investment opportunity, despite current volatility and ownership pressure.
Evonik Industries AG (EVKIF) Q3 2024 Earnings Call Transcript
Evonik Industries AG (OTCPK:EVKIF) Q3 2024 Earnings Conference Call November 6, 2024 5:00 AM ET Company Participants Christian Kullmann - Chief Executive Officer Maike Schuh - Chief Financial Officer Tim Lange - Head, Investor Relations Conference Call Participants Thomas Wrigglesworth - Morgan Stanley Chetan Udeshi - JPMorgan Andreas Heine - Stifel Sebastian Bray - Berenberg Martin Roediger - Kepler Cheuvreux Jaideep Pandya - On Field Research Operator Ladies and gentlemen, welcome to the Evonik Industries Q3 2024 Earnings Conference Call. I'm Vicky, the chorus call operator.
Evonik - I Continue To Be Long Here
Evonik has shown growth and strong performance in 3Q and 4Q23, with a 19% increase in share price since the last article. The company is undergoing a strategic realignment and investing in future technologies, leading to long-term growth opportunities. Evonik remains undervalued, with a positive outlook for 2024E and potential for 15%+ annualized upside, making it a "BUY".
